Laser scleral microporation may solve biomechanical problem of presbyopia
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Alex Lopez of Ace Vision Group discusses laser scleral microporation for presbyopia.
Lopez said the GenII device can potentially deliver improved near vision without compromising distance vision in patients with presbyopia. The company plans to do a study in the United States in 2026, potentially leading to commercial availability in the U.S. in 2027.
“Presbyopia is a biomechanical problem with refractive consequences,” he said. “We finally have a solution that can potentially restore biomechanical movement and help patients regain that near vision they want in a natural way.”
Explore More Articles
Scleral approaches to presbyopia moving from niche to mainstream
Among the many options for presbyopia, scleral approaches stand out for their unique attempt to tackle the roots of the problem, restoring physiological function rather than aiming for optical compensation. They had a slow takeoff and limited acceptance, but step by step, through a long path of research and technological upgrades, they continue to move …
read moreThe Future of the Aging Eye
AnnMarie Hipsley, the Founder and CEO of Ace Vision Group (AVG), a Delaware, USA- based company developing innovative therapeutics for age-related ocular dysfunctions, talks to The Ophthalmologist about her background and work with AVG, and the company’s short- and long-term goals. She explains how the Group has utilized artificial intelligence and virtual reality platforms to …
Show videoAce Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
read more